Scientific Council Member
Irwin Lucki, Ph.D.
Irwin Lucki, Ph.D.
Emeritus Professor of Psychology in Psychiatry, University of Pennsylvania
Professor and Chair, Department of Pharmacology
2004 Distinguished Investigator Grantee
The research interests of the laboratory have focused on defining the role of specific neurotransmitters in the behavioral effects of drugs used in the treatment of psychiatric disorders. Animal models for depression and anxiety are used to evaluate the potential efficacy of different neurotransmitter and peptide receptors for clinical therapeutic effects, to identify brain regions associated with behavioral responses to drugs, and to construct and evaluate pharmacological models for improving the efficacy of psychiatric medications. The participation of genetic and pharmacological modifications of neural circuits in depression, anxiety and neuroendocrine regulation associated with behavioral stress has specifically been investigated. Microdialysis procedures are used to measure the release of neurotransmitters in discrete regions of awake freely-moving rats or mice. These studies provide information on the regulation of the release of neurotransmitters in different brain regions, determine environmental and behavioral conditions that alter the release of neurotransmitters, and measure the effects of drugs during behavioral performance. Finally, studies of different inbred mouse strains or knockout mice are used to examine genetic factors associated with complex behaviors and for identifying mechanisms underlying the behavioral effects of psychotherapeutic medications.
Most recently, our research program has focused on establishing neural mechanisms through animal behavior models for the clinical use of rapid-acting antidepressants for treatment-resistant forms of depression and anxiety. Studies have focused on glutamatergic compounds, such as ketamine, and diverse opioid compounds, such as buprenorphine, nalmefene and selective kappa opioid receptor antagonists. Behavioral studies have shown long-lasting antidepressant-like effects for these compounds under conditions where established antidepressants are ineffective. Pharmacological studies are examining the mechanisms underlying the unusually long duration of their behavioral effects.
Learn More About the Foundation
The Brain & Behavior Research Foundation is a global nonprofit organization focused on improving the understanding, prevention and treatment of psychiatric and mental illnesses.
Beginning in 1987, the Brain & Behavior Research Foundation was providing seed money to neuroscientists to invest in “out of the box” research that the government and other sources were unwilling to fund. Today, Brain & Behavior Research Foundation is still the leading, private philanthropy in the world in this space.
Meet the people who make up the Brain & Behavior Research Foundation. Our staff of experts, passionate Board of Directors, and Scientific Council which includes Nobel prize winners and chairs of psychiatric departments around the world.
We take our responsibility to our donors seriously and believe that our financial operations must be transparent. We're proud to say that 100% of your contribution for research is invested directly in research grants.